Concord Biotech Limited
NSE: CONCORDBIO BSE: CONCORDBIO
Prev Close
1521.4
Open Price
1521.4
Volume
251,941
Today Low / High
1506.05 / 1655
52 WK Low / High
1327.05 / 2664
Range
1,562 - 1,727
Prev Close
1521.75
Open Price
1525.45
Volume
3,423
Today Low / High
1518.35 / 1651
52 WK Low / High
1326.9 / 2658
Range
1,560 - 1,724
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1644.45 (target range: 1,562 - 1,727), reflecting a change of 123.05 (8.08795%). On the BSE, it is listed at 1641.7 (target range: 1,560 - 1,724), showing a change of 119.95 (7.88237%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Concord Biotech Limited Graph
Concord Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking Target Price for Concord Biotech Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 1,644, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,641.70 | 1,658.12 | 1,492.31 - 1,823.93 |
| 1,674.53 | 1,339.63 - 2,009.44 | ||
| 1,690.95 | 1,183.67 - 2,198.24 | ||
| Bearish Scenario | 1,641.70 | 1,625.28 | 1,462.75 - 1,787.81 |
| 1,608.87 | 1,287.09 - 1,930.64 | ||
| 1,592.45 | 1,114.71 - 2,070.18 |
Overview of Concord Biotech Limited
ISIN
INE338H01029
Industry
Biotechnology
Vol.Avg
177,681
Market Cap
172,580,114,330
Last Dividend
8.75
Official Website
IPO Date
2023-08-18
DCF Diff
1,428.86
DCF
93
Financial Ratios Every Investor Needs
Stock Dividend of CONCORDBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-06-21 | June 21, 24 | 8.75 | 8.75 | 2024-06-22 | 2024-07-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 998.06 Cr | 244.78 Cr | 753.27 Cr | 0.7547 | 22.90 Cr | 11.13 Cr | 626.19 Cr | 308.10 Cr | 29.45 | 465.91 Cr | 0.3087 |
| 2023-03-31 | 853.17 Cr | 180.21 Cr | 672.96 Cr | 0.7888 | 32.83 Cr | 10.50 Cr | 326.52 Cr | 240.09 Cr | 22.95 | 383.22 Cr | 0.2814 |
| 2022-03-31 | 708.44 Cr | 177.92 Cr | 530.52 Cr | 0.7489 | 29.09 Cr | 10.58 Cr | 243.96 Cr | 174.93 Cr | 16.72 | 297.34 Cr | 0.2469 |
| 2021-03-31 | 604.05 Cr | 120.33 Cr | 483.73 Cr | 0.8008 | 0.00 Cr | 7.09 Cr | 306.89 Cr | 234.89 Cr | 22.45 | 341.74 Cr | 0.3889 |
| 2020-03-31 | 512.33 Cr | 138.08 Cr | 374.25 Cr | 0.7305 | 0.00 Cr | 6.30 Cr | 194.00 Cr | 169.11 Cr | 16.16 | 214.05 Cr | 0.3301 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 15.14 Cr | 1,700.71 Cr | 174.06 Cr | 1,526.6455 Cr | 9.74 Cr | -5.40 Cr | 207.95 Cr | 786.48 Cr | 3.66 Cr | 0.00 Cr | -263.36 Cr | 142.1554 Cr |
| 2023-03-31 | 3.50 Cr | 1,513.98 Cr | 223.98 Cr | 1,290.0010 Cr | 31.55 Cr | 28.05 Cr | 212.32 Cr | 765.48 Cr | 0.00 Cr | 0.00 Cr | -168.12 Cr | 191.8460 Cr |
| 2022-03-31 | 0.67 Cr | 1,312.80 Cr | 209.57 Cr | 1,103.2230 Cr | 62.49 Cr | 61.83 Cr | 195.12 Cr | 643.56 Cr | 0.00 Cr | 0.00 Cr | -160.85 Cr | 155.1680 Cr |
| 2021-03-31 | 5.14 Cr | 1,182.55 Cr | 183.17 Cr | 999.3730 Cr | 89.28 Cr | 84.14 Cr | 153.61 Cr | 557.75 Cr | 0.00 Cr | 0.00 Cr | -195.70 Cr | 105.7390 Cr |
| 2020-03-31 | 45.62 Cr | 940.52 Cr | 170.28 Cr | 648.5830 Cr | 50.96 Cr | 5.34 Cr | 111.23 Cr | 380.91 Cr | 0.00 Cr | 0.00 Cr | 0.82 Cr | 115.0950 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 265.4671 Cr | -154.6093 Cr | -99.2149 Cr | 179.7786 Cr | 11.6429 Cr | 15.1421 Cr | -85.6885 Cr | 308.1032 Cr | -26.5036 Cr | -71.4529 Cr | 4.3609 Cr |
| 2023-03-31 | 246.0018 Cr | -157.9501 Cr | -85.2194 Cr | 100.9170 Cr | 2.8323 Cr | 3.4992 Cr | -145.0848 Cr | 322.0134 Cr | -26.5961 Cr | -53.5635 Cr | -17.2273 Cr |
| 2022-03-31 | 207.4750 Cr | -111.7880 Cr | -100.1640 Cr | 51.9700 Cr | -4.4770 Cr | 0.6670 Cr | -155.5050 Cr | 237.5180 Cr | -26.6557 Cr | -70.5210 Cr | -41.5090 Cr |
| 2021-03-31 | 166.8170 Cr | -195.2050 Cr | 31.1240 Cr | -37.3590 Cr | 2.7360 Cr | 5.1440 Cr | -204.1760 Cr | 312.7200 Cr | 38.3210 Cr | -5.7060 Cr | -42.3770 Cr |
| 2020-03-31 | 154.8440 Cr | -112.7790 Cr | -43.4160 Cr | -0.6230 Cr | -1.3510 Cr | 2.4080 Cr | -155.4670 Cr | 169.1120 Cr | 37.4200 Cr | -80.5450 Cr | -19.5140 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 244.22 Cr | 52.40 Cr | 191.82 Cr | 0.7854 | 0.00 Cr | 75.92 Cr | 7.26 | 114.51 Cr | 0.3109 |
| 2024-09-30 | 310.18 Cr | 76.32 Cr | 233.86 Cr | 0.7540 | 123.36 Cr | 95.74 Cr | 9.15 | 143.75 Cr | 0.3087 |
| 2024-06-30 | 215.80 Cr | 48.30 Cr | 167.50 Cr | 0.7762 | 135.84 Cr | 59.59 Cr | 5.70 | 91.59 Cr | 0.2761 |
| 2024-03-31 | 318.97 Cr | 88.84 Cr | 230.13 Cr | 0.7215 | 129.18 Cr | 95.02 Cr | 9.08 | 145.10 Cr | 0.2979 |
| 2023-12-31 | 240.80 Cr | 47.09 Cr | 193.71 Cr | 0.8045 | 103.60 Cr | 77.57 Cr | 7.41 | 114.12 Cr | 0.3222 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 7.40 Cr | 310.89 Cr | 318.29 Cr | 0.00 Cr | 250.42 Cr | 934.65 Cr | 806.03 Cr | 1,764.34 Cr | 173.97 Cr |
| 2024-06-30 | -281.67 Cr | 563.33 Cr | 281.67 Cr | 0.00 Cr | 0.00 Cr | 281.67 Cr | 0.00 Cr | 0.00 Cr | -1,526.65 Cr |
| 2024-03-31 | 15.14 Cr | 295.03 Cr | 310.18 Cr | 369.04 Cr | 207.95 Cr | 896.23 Cr | 786.48 Cr | 1,700.71 Cr | 174.06 Cr |
| 2023-12-31 | -225.07 Cr | 450.14 Cr | 225.07 Cr | 0.00 Cr | 0.00 Cr | 225.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 6.08 Cr | 245.49 Cr | 251.56 Cr | 267.04 Cr | 219.86 Cr | 755.65 Cr | 777.60 Cr | 1,551.03 Cr | 196.72 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 59.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 95.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 77.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 81.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-06-30 | 54.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹312.20 | ₹374,827,320,000.00 | ₹2,116,013.00 |
| Syngene International Limited | SYNGENE | ₹650.00 | ₹260,840,646,950.00 | ₹202,178.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹192.10 | ₹254,676,229,220.00 | ₹2,764,417.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,643.45 | ₹171,931,493,890.00 | ₹251,710.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹789.00 | ₹136,864,216,380.00 | ₹388,513.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹600.75 | ₹95,688,060,750.00 | ₹358,426.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹614.80 | ₹49,480,825,440.00 | ₹242,967.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹204.72 | ₹32,096,615,760.00 | ₹205,540.00 |
| Zota Health Care Limited | ZOTA | ₹812.25 | ₹22,261,823,100.00 | ₹42,771.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1952
Gender: male
Year Born: 1982
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Concord Biotech Limited
The CEO is Mr. Ankur Vaid.
The current price is ₹1,649.65.
The range is ₹1327.05-2664.
The market capitalization is ₹17,258.01 crores.
The dividend yield is 0.53%.
The P/E ratio is 52.87.
The company operates in the Healthcare sector.
Overview of Concord Biotech Limited (ISIN: INE338H01029) is a leading Biotechnology in India. With a market capitalization of ₹17,258.01 crores and an average daily volume of 177,681 shares, it operates in the Biotechnology. The company last declared a dividend of ₹8.75.